Roche plans Phase III trial for diabetes candidate aleglitazar
This article was originally published in Scrip
Executive Summary
Roche is to begin Phase III studies of its oral peroxisome proliferator-activated receptor (PPAR) α/γ co-agonist aleglitazar (R1439) in patients with type 2 diabetes during the second half of this year, following positive results in a Phase II trial which were published in The Lancet on June 9th, and presented at the American Diabetes Association (ADA) meeting in New Orleans.